|Keyword||CPC||PCC||Volume||Score||Length of keyword|
Now in a phase 3 study, narsoplimab was evaluated in a staged phase 2 study assessing safety and effectiveness in high-risk patients with IgA nephropathy (IgAN). Methods: Substudy 1 was a single-arm open-label study of 12 weekly infusions and tapered corticosteroids, with 6 weeks of follow-up.Is it safe to take narsoplimab for IgAN?
This interim analysis suggests that narsoplimab treatment is safe, is well tolerated, and may result in clinically meaningful reductions in proteinuria and stability of eGFR in high-risk patients with advanced IgAN. Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA NephropathyWho is eligible for membranous nephropathy trial of rituximab?
MEmbranous Nephropathy Trial Of Rituximab (MENTOR) Type 1 or 2 diabetes mellitus: to exclude proteinuria secondary to diabetic nephropathy. Patients who have recent history of steroid induced diabetes but no evidence on renal biopsy performed within 6 months of entry into the study are eligible for enrollment.What do you need to know about Naropin use?
The medication is used to provide anesthesia during a surgery or C-section, or to ease labor pains. Naropin may also be used for purposes not listed in this medication guide. Before receiving Naropin, tell your doctor if you have ever had an allergic reaction to any type of numbing medicine.